BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18245008)

  • 1. Prognostic value of initial clinical disease stage after achieving pathological complete response.
    Dawood S; Broglio K; Kau SW; Islam R; Symmans WF; Buchholz TA; McGuire SE; Meric-Bernstam F; Cristofanilli M; Hortobágyi GN; Gonzalez-Angulo AM
    Oncologist; 2008 Jan; 13(1):6-15. PubMed ID: 18245008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of body mass index in locally advanced breast cancer.
    Dawood S; Broglio K; Gonzalez-Angulo AM; Kau SW; Islam R; Hortobagyi GN; Cristofanilli M
    Clin Cancer Res; 2008 Mar; 14(6):1718-25. PubMed ID: 18347172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
    Hennessy BT; Gonzalez-Angulo AM; Hortobagyi GN; Cristofanilli M; Kau SW; Broglio K; Fornage B; Singletary SE; Sahin A; Buzdar AU; Valero V
    Cancer; 2006 Mar; 106(5):1000-6. PubMed ID: 16444747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
    Hennessy BT; Hortobagyi GN; Rouzier R; Kuerer H; Sneige N; Buzdar AU; Kau SW; Fornage B; Sahin A; Broglio K; Singletary SE; Valero V
    J Clin Oncol; 2005 Dec; 23(36):9304-11. PubMed ID: 16361629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends for inflammatory breast cancer: is survival improving?
    Gonzalez-Angulo AM; Hennessy BT; Broglio K; Meric-Bernstam F; Cristofanilli M; Giordano SH; Buchholz TA; Sahin A; Singletary SE; Buzdar AU; Hortobágyi GN
    Oncologist; 2007 Aug; 12(8):904-12. PubMed ID: 17766649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifocal breast cancer in women < or =35 years old.
    Litton JK; Eralp Y; Gonzalez-Angulo AM; Broglio K; Uyei A; Hortobagyi GN; Arun B
    Cancer; 2007 Oct; 110(7):1445-50. PubMed ID: 17676585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
    Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
    Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.
    Cristofanilli M; Valero V; Buzdar AU; Kau SW; Broglio KR; Gonzalez-Angulo AM; Sneige N; Islam R; Ueno NT; Buchholz TA; Singletary SE; Hortobagyi GN
    Cancer; 2007 Oct; 110(7):1436-44. PubMed ID: 17694554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes and prognostic factors of patients with breast cancer: a retrospective review.
    Tantivatana T; Chongthanakorn M; Rongsriyam K; Katanyoo K
    J Med Assoc Thai; 2009 Aug; 92(8):1084-93. PubMed ID: 19694335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
    Secord AA; Havrilesky LJ; O'Malley DM; Bae-Jump V; Fleming ND; Broadwater G; Cohn DE; Gehrig PA
    Gynecol Oncol; 2009 Sep; 114(3):442-7. PubMed ID: 19560193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
    Hoekstra AV; Kim RJ; Small W; Rademaker AW; Helenowski IB; Singh DK; Schink JC; Lurain JR
    Gynecol Oncol; 2009 Aug; 114(2):273-8. PubMed ID: 19428094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
    Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
    Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment.
    Bertucci F; Tarpin C; Charafe-Jauffret E; Bardou VJ; Braud AC; Tallet A; Gravis G; Viret F; Gonçalves A; Houvenaeghel G; Blaise D; Jacquemier J; Maraninchi D; Viens P
    Bone Marrow Transplant; 2004 May; 33(9):913-20. PubMed ID: 15004544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical factors in prediction of prognosis after anterior resection with total mesorectal excision for carcinoma of the rectum.
    Szynglarewicz B; Matkowski R; Forgacz J; Pudelko M; Smorag Z; Dryl J; Kornafel J
    Oncol Rep; 2007 Feb; 17(2):471-5. PubMed ID: 17203190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoluminal resection for sessile neoplasia in the GI tract is associated with a low recurrence rate and a high 5-year survival rate.
    Wang AY; Ahmad NA; Zaidman JS; Brensinger CM; Lewis JD; Long WB; Kochman ML; Ginsberg GG
    Gastrointest Endosc; 2008 Jul; 68(1):160-9. PubMed ID: 18577483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.